

Floriana Morgillo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6782352/floriana-morgillo-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

112
papers

4,658
citations

34
h-index

67
g-index

119
ext. papers

5,408
ext. citations

6.1
avg, IF

5.32
L-index

#	Paper	IF	Citations
112	Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022 , 41, 109	12.8	0
111	Immunotherapy for head and neck cancer: present and future.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 103679	7	2
110	Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 169, 103538	7	2
109	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. <i>BMC Cancer</i> , 2021 , 21, 549	4.8	0
108	Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 15	12.8	6
107	Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 1758835920949418	5.4	11
106	Dual inhibition of TGF β and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. <i>Medical Oncology</i> , 2021 , 38, 24	3.7	2
105	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. <i>Lung Cancer</i> , 2021 , 152, 165-173	5.9	11
104	Hypothalamic-Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies. <i>Cancers</i> , 2021 , 13,	6.6	1
103	PercuTwist tracheostomy in an intubated patient with tracheal stent. <i>Asian Cardiovascular and Thoracic Annals</i> , 2021 , 29, 431-433	0.6	
102	Metformin: An old drug against old age and associated morbidities. <i>Diabetes Research and Clinical Practice</i> , 2020 , 160, 108025	7.4	32
101	Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania Luigi Vanvitelli. <i>ESMO Open</i> , 2020 , 5,	6	6
100	Efficacy and safety of immunotherapy in non-small cell lung cancer patients with poor performance status.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e21601-e21601	2.2	3
99	Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population. <i>OncoTargets and Therapy</i> , 2020 , 13, 867-876	4.4	7
98	Baseline IFN- γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. <i>Scientific Reports</i> , 2020 , 10, 17626	4.9	3
97	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020 , 138, 1-10	7.5	9
96	Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer. <i>ESMO Open</i> , 2020 , 5, e000753	6	12

95	How I treat malignant pleural mesothelioma. <i>ESMO Open</i> , 2020 , 4, e000669	6	4
94	Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 41	12.8	37
93	Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 253	12.8	40
92	Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 236	12.8	12
91	Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials. <i>Lung Cancer</i> , 2019 , 133, 62-68	5.9	1
90	Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 178	12.8	19
89	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 845-855	6.1	30
88	<i>Urtica dioica</i> L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis. <i>Scientific Reports</i> , 2019 , 9, 4986	4.9	7
87	Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. <i>Cancers</i> , 2019 , 11,	6.6	17
86	Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma. <i>Thoracic Cancer</i> , 2019 , 10, 2308-2311	3.2	1
85	Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study. <i>ESMO Open</i> , 2019 , 4, e000536	6	12
84	ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer. <i>EBioMedicine</i> , 2019 , 39, 5-6	8.8	2
83	Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 810-820	8.9	19
82	Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives. <i>Frontiers in Endocrinology</i> , 2018 , 9, 115	5.7	17
81	Role and targeting of anaplastic lymphoma kinase in cancer. <i>Molecular Cancer</i> , 2018 , 17, 30	42.1	34
80	Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota. <i>Neoplasia</i> , 2018 , 20, 721-733	6.4	47
79	Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells. <i>Oncotarget</i> , 2018 , 9, 19273-19382	3.9	5
78	HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	50

77	Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report. <i>Oncology Letters</i> , 2017 , 13, 979-983	2.6	
76	Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. <i>Cancer Treatment Reviews</i> , 2017 , 53, 61-69	14.4	77
75	Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. <i>Oncotarget</i> , 2017 , 8, 82773-82783	3.3	5
74	Phosphatidylinositol 3-kinase (PI3K)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells. <i>Oncotarget</i> , 2017 , 8, 76479-76491	3.3	20
73	Implication of the Hedgehog pathway in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017 , 23, 4330-4340	5.6	33
72	Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer. <i>ESMO Open</i> , 2017 , 2, e000132	6	41
71	Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. <i>ESMO Open</i> , 2017 , 2, e000177	6	19
70	Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 7447-7458	8.3	19
69	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. <i>World Journal of Gastroenterology</i> , 2017 , 23, 4675-4688	5.6	70
68	Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. <i>Oncotarget</i> , 2017 , 8, 23020-23032	3.3	26
67	Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. <i>Oncotarget</i> , 2017 , 8, 67592-67604	3.3	11
66	Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. <i>Oncotarget</i> , 2017 , 8, 68305-68316	3.3	20
65	Mechanisms of resistance to EGFR-targeted drugs: lung cancer. <i>ESMO Open</i> , 2016 , 1, e000060	6	229
64	Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. <i>ESMO Open</i> , 2016 , 1, e000088	6	69
63	Therapies in the pipeline for small-cell lung cancer. <i>British Medical Bulletin</i> , 2016 , 119, 37-48	5.4	8
62	Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. <i>Oncotarget</i> , 2016 , 7, 4265-78	3.3	51
61	Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review. <i>Oncology Letters</i> , 2016 , 12, 4505-4509	2.6	
60	BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016 , 17, 461-465	4.9	27

59	Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2016 , 18, 59	6.3	28
58	Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. <i>Clinical Cancer Research</i> , 2015 , 21, 2975-83	12.9	51
57	SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 4686-97	12.9	93
56	A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial. <i>Clinical Lung Cancer</i> , 2015 , 16, 57-9	4.9	16
55	Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1133-41	8.9	133
54	Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. <i>Clinical Cancer Research</i> , 2015 , 21, 4153-64	12.9	13
53	Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. <i>Annals of Translational Medicine</i> , 2015 , 3, 81	3.2	9
52	AXL is an oncotarget in human colorectal cancer. <i>Oncotarget</i> , 2015 , 6, 23281-96	3.3	45
51	Baseline neutrophil-lymphocyte ratio as a prognostic factor for patients with resectable gastric cancer undergoing adjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15018-e15018	2.2	
50	Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 809-21	5.9	21
49	Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2014 , 15, 173-81	4.9	50
48	Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. <i>Clinical Cancer Research</i> , 2014 , 20, 3775-86	12.9	76
47	Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. <i>Biomedicine</i> , 2014 , 2, 345-358	4.8	24
46	Combination nab-paclitaxel (Nab-P) plus gemcitabine (G) as first-line treatment in advanced pancreatic cancer (APC): Our experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15257-e15257	2.2	
45	Incidence and prognostic significance of HER2 overexpression in gastric cancer (GC): A monoinstitutional retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 160-160	2.2	
44	Postoperative chemoradiation FOLFOX 4-based for R1 resected gastric cancer: A retrospective mono-institutional study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 143-143	2.2	
43	Metformin in lung cancer: rationale for a combination therapy. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 1401-9	5.9	22
42	Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?. <i>Lung Cancer</i> , 2013 , 80, 352-3	5.9	

41	Emerging VEGF-receptor inhibitors for colorectal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2013 , 18, 25-37	3.7	24
40	Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. <i>International Journal of Cancer</i> , 2013 , 133, 2089-101	7.5	70
39	Increased TGF- β s as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. <i>Clinical Cancer Research</i> , 2013 , 19, 6751-65	12.9	111
38	Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?. <i>Therapeutic Advances in Medical Oncology</i> , 2013 , 5, 51-72	5.4	10
37	The value of matrix metalloproteinase-9 and vascular endothelial growth factor receptor 1 pathway in diagnosing indeterminate pleural effusion. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2013 , 16, 263-9	1.8	25
36	Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. <i>Clinical Cancer Research</i> , 2013 , 19, 3508-19	12.9	88
35	Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases. <i>Oncology Reports</i> , 2013 , 30, 2992-8	3.5	10
34	Critical appraisal of the use of regorafenib in the management of colorectal cancer. <i>Cancer Management and Research</i> , 2013 , 5, 49-55	3.6	5
33	Basic Science of Lung Cancer in Older Patients 2013 , 3-12		
32	Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1830-1844	8.9	17
31	Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 949-59	5.9	18
30	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3002-11	2.2	193
29	Control of post-thoracotomy pain by transcutaneous electrical nerve stimulation: effect on serum cytokine levels, visual analogue scale, pulmonary function and medication. <i>European Journal of Cardio-thoracic Surgery</i> , 2012 , 41, 861-8; discussion 868	3	48
28	Clinical results with EGFR inhibitors in colorectal cancer 2012 , 44-59		
27	Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2011 , 71, 283-90	5.9	24
26	Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. <i>PLoS ONE</i> , 2011 , 6, e28841	3.7	34
25	Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2011 , 12, 420-4	1.8	35
24	Trastuzumab Resistance in Breast Cancer 2011 , 51-60		

23	Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study. <i>Cancer Investigation</i> , 2010 , 28, 820-7	2.1	16
22	Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. <i>Clinical Cancer Research</i> , 2010 , 16, 4990-5001	12.9	70
21	Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. <i>Lung Cancer</i> , 2010 , 67, 86-92	5.9	19
20	Resistance mechanisms of tumour cells to EGFR inhibitors. <i>Clinical and Translational Oncology</i> , 2009 , 11, 270-5	3.6	17
19	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 519-27	19.4	341
18	Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 1698-707	6.1	22
17	Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. <i>Journal of Cellular Physiology</i> , 2008 , 216, 698-707	7	29
16	The use of xenograft models for the selection of cancer treatments with the EGFR as an example. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 65, 200-11	7	50
15	Chronic inflammation and oxidative stress in human carcinogenesis. <i>International Journal of Cancer</i> , 2007 , 121, 2381-6	7.5	661
14	Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. <i>Differentiation</i> , 2007 , 75, 788-99	3.5	65
13	A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics. <i>Clinical Lung Cancer</i> , 2007 , 8, 568-71	4.9	18
12	Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. <i>Clinical Cancer Research</i> , 2007 , 13, 2795-803	12.9	222
11	Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. <i>Expert Opinion on Drug Discovery</i> , 2007 , 2, 335-48	6.2	3
10	Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy. <i>Current Cancer Therapy Reviews</i> , 2007 , 3, 117-126	0.4	
9	Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors. <i>Current Cancer Therapy Reviews</i> , 2007 , 3, 276-283	0.4	
8	Combination of standard chemotherapy and targeted agents. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S19-23		2
7	Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment. <i>Targeted Oncology</i> , 2006 , 1, 123-129	5	3
6	Lonafarnib in cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2006 , 15, 709-19	5.9	38

5	Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. <i>Cancer Research</i> , 2006 , 66, 10100-11	10.1	291
4	Resistance to epidermal growth factor receptor-targeted therapy. <i>Drug Resistance Updates</i> , 2005 , 8, 298-310	23.2	66
3	Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1272-88	8.7	89
2	Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. <i>Cancer</i> , 2004 , 100, 270-8	6.4	90
1	Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. <i>Journal of Interferon and Cytokine Research</i> , 2002 , 22, 1129-35	3.5	62